SomaLogic (SomaLogic) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SomaLogic 5-Year EBITDA Growth Rate?

SomaLogic's EBITDA per Share for the three months ended in Sep. 2023 was $-0.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of SomaLogic's 5-Year EBITDA Growth Rate

For the Health Information Services subindustry, SomaLogic's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SomaLogic's 5-Year EBITDA Growth Rate Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where SomaLogic's 5-Year EBITDA Growth Rate falls into.

SomaLogic 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

SomaLogic (NAS:SLGC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

SomaLogic 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of SomaLogic's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

SomaLogic (SomaLogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2945 Wilderness Place, Boulder, CO, USA, 80301

Website

https://www.somalogic.com

SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

Executives

Alison Marie Roelke	officer: Chief People Officer	900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich	officer: Interim CEO	C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez	officer: General Counsel	6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs	director	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan	director	C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey	director	8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman	officer: Chief Financial Officer	C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies	director	C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post	director	998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis	director	13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake	director	C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi	director